SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Boston Scientific Corporation BSX-PA NYSE

NYSE • Healthcare • Medical - Devices • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Boston Scientific Corporation (BSX-PA) is a Medical - Devices company in the Healthcare sector, currently trading at $122.18. It has a SharesGrow Score of 76/100, indicating a strong investment profile with 5 out of 7 criteria passed.

Financials: revenue is $20.1B, +16.6%/yr average growth. Net income is $2.9B, growing at +66.8%/yr. Net profit margin is 14.4% (healthy). Gross margin is 69% (+0.6 pp trend).

Balance sheet: total debt is $12.4B against $24.2B equity (Debt-to-Equity (D/E) ratio 0.51, moderate). Current ratio is 1.62 (strong liquidity). Debt-to-assets is 28.4%. Total assets: $43.7B.

Analyst outlook: 12 / 13 analysts rate BSX-PA as buy (92%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 15/100 (Fail), Growth 90/100 (Pass), Past 100/100 (Pass), Health 83/100 (Pass), Moat 86/100 (Pass), Future 100/100 (Pass), Income 55/100 (Partial).

BSX-PA SharesGrow Score Overview

76/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 15/100

Valuation — P/E, PEG, Forward PEG

GROWTH 90/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 83/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 86/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 55/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BSX-PA

BSX-PA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

BSX-PA: +16.6%/yr revenue is, +66.8%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

BSX-PA: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet BSX-PA: Debt-to-Equity (D/E) ratio 0.51 (moderate), Current ratio is 1.62 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

BSX-PA: Gross margin is 69% (+0.6 pp trend), $175B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 86/100. ≥ 70 = Pass.

View details →

Analyst outlook: 12 / 13 analysts rate BSX-PA as buy (92%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

BSX-PA: Net profit margin is 14.4%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range97.37-129.12

Volume2.06M

Avg Volume (30D)191.49K

Market Cap$175.45B

Beta (1Y)0.80

Dividend Yield$5.5000

Share Statistics

EPS (TTM)1.96

Shares Outstanding$1.48B

IPO Date2020-05-22

Employees45,000

CEOMichael F. Mahoney

Financial Highlights & Ratios

Revenue (TTM)$20.07B

Gross Profit$13.85B

EBITDA$3.73B

Net Income$2.89B

Operating Income$3.97B

Total Cash$2.05B

Total Debt$12.42B

Net Debt$10.37B

Total Assets$43.67B

Price / Earnings (P/E)62.3

Price / Sales (P/S)8.74

Analyst Forecast

Rating ConsensusBuy

Analysts Covering13

Buy 92% Hold 8% Sell 0%

Company Info

CountryUS

ExchangeNYSE

CurrencyUSD

ISINUS1011372067

Price Chart

BSX-PA

Boston Scientific Corporation ↗ · NYSE

Healthcare • Medical - Devices

97.37 52WK RANGE 129.12

People Also View

Becton, Dickinson and Company

Citizens Financial Group, Inc.

Digital Realty Trust, Inc.

Eli Lilly and Company

Johnson & Johnson

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message